Core Insights - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, developing noninvasive tools to identify pain sources in spinal discs, potentially transforming care standards in a $134 billion market [1][5] Group 1: Nociscan Technology - The Nociscan platform utilizes augmented intelligence algorithms and biomarkers, representing a significant advancement in chronic pain treatment [1] - Nociscan has been selected for the LIFEHAB Trial in Norway, which aims to evaluate its MRS biomarkers for determining optimal treatment options for chronic low back pain [2] - Aclarion's technology is protected by 40 issued patents and 12 pending applications, indicating strong intellectual property backing [1] Group 2: Clinical Trials and Research - Aclarion is awaiting results from a completed trial in Rome and two NIH-funded studies in the U.S. that examine Nociscan's role in treating low back pain [2] - The CLARITY trial will enroll up to 300 patients across eight sites to validate Nociscan's ability to improve surgical outcomes [2] Group 3: Payer Coverage and Partnerships - Key Opinion Leader (KOL) surgeons are instrumental in advocating for Nociscan and influencing insurance coverage decisions, with Aclarion collaborating with 10 top spine surgeons globally [3] - The company is expanding partnerships in the U.S., particularly targeting personal injury and worker compensation sectors with its Nociscan technology [3]
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology